NCT01088906终止2 期
Study of Pemetrexed Disodium Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous Cell Lung Cancer: a Phase IIA Pharmacogenomic Trial
Spanish Lung Cancer Group8 个研究点 分布在 1 个国家目标入组 57 人开始时间: 2010年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 57
- 试验地点
- 8
- 主要终点
- Objective Response Rate
研究概览
简要总结
This is a study of pemetrexed disodium plus cisplatin as first-line therapy in patients with advanced non-squamous cell lung cancer. This is a phase IIA pharmacogenomic trial.
详细描述
This is a non-randomized, phase IIA pharmacogenomic, open label, uncontrolled, efficacy study in patients with advanced non-squamous cell lung cancer as a first line therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic or cytologic diagnosis of non-squamous NSCLC, that is not amenable to curative treatment with surgery or radiation therapy. This population encompasses advanced stage patients with select stage IIIB (with pleural or pericardial effusion) or stage IV disease. Histologic or cytologic documentation of recurrence is required in patients who were previously completely resected and now have progressive disease.
- •Tissue must be available to generate and apply the genomics predictor. If not obtained at the time of diagnosis, then subject must consent to another biopsy. If patient had prior radiation therapy, tissue biopsy for genomics analysis must be outside radiation field.
- •At least one, non-radiated, measurable lesion by RECIST criteria.
- •ECOG performance status of 0 or 1
- •No prior chemotherapy, biologic or targeted therapy for any malignancy.
- •Prior radiation therapy is permitted if ≥1 week since completion of radiation treatment. Radiation must be <25% of bone marrow reserve.
- •Age greater than 18 years.
- •No previous or concomitant malignancy in the past 5 years other than surgical management for carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin.
- •No other serious medical or psychiatric illness.
- •Signed informed consent.
- •Females of child-bearing potential (not surgically sterilized and between menarche and 1 year post menopause) must test negative for pregnancy within 7 days prior to or at the time of enrollment based on a serum pregnancy test. Both sexually active males and females of reproductive potential must agree to use a reliable method of birth control, as determined by the patient and their health care team, during the study and for 3 months following the last dose of study drug.
- •Required laboratory data within two weeks of enrollment:
- •ANC or AGC greater than 1500 per uL
- •Platelets greater than 100,000 per uL
- •Total bilirubin less than 1.5mg/dL
- •Creatinine clearance greater than or equal to 45 ml/min.
- •SGOT/SGPT less than or equal to 3x/ULN except in presence of known hepatic metastases in which it may be up to 5x ULN.
排除标准
- •Patients with squamous cell NSCLC.
- •Treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
- •Concurrent administration of any other anti-tumor therapy.
- •Inability to comply with protocol or study procedures.
- •Active infection requiring IV antibiotics, antifungal or antiviral agents, that in the opinion of the investigator would compromise the patient's ability to tolerate therapy.
- •Documented symptomatic or untreated central nervous system (CNS) metastases (except if adequately treated and stable for at least 2 weeks).
- •Major surgery within 2 weeks of study or other serious concomitant systemic disorders that, in the opinion or the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study.
- •Myocardial infarction having occurred less than 6 months before inclusion, any known uncontrolled arrhythmia, symptomatic angina pectoris, active ischemia or cardiac failure not controlled by medications.
- •Have peripheral neuropathy of CTCAE Grade 1 or higher
- •Contraindications to corticosteroids.
- •Inability or unwillingness to take folic acid or vitamin B12 supplementation.
- •Unwillingness to stop taking herbal supplements while on study.
- •Presence of clinically significant third-space fluid collections (for example, ascites or pleural effusions) that cannot be controlled by drainage or other procedures prior to study entry and throughout study enrollment as the distribution of pemetrexed in this fluid space is not fully understood.
- •Recent (within 30 days before enrollment) or concurrent yellow fever vaccination.
- •Have prior known allergic/hypersensitivity reaction to any of the components of study treatment
- •Inability to discontinue administration of aspirin at a dose greater than 1300 mg/day or other non-steroidal anti-inflammatory agents for 2 days before, the day of, and 2 days after the dose of pemetrexed (5 days for long-acting agents such as piroxicam).
- •Female patients that is pregnant or breast-feeding.
研究组 & 干预措施
1 ARM
Experimental
pemetrexed 500 mg/m2 IV + cisplatin 75 mg/m2 every 21 days
干预措施: Pemetrexed/Cisplatin (Drug)
结局指标
主要结局
Objective Response Rate
时间窗: From start of treatment to end of follow up, up to 24 months
The percentage of patients who have experienced a tumor response since the start of treatment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
次要结局
- Overall Survival(From the date of enrollment until end of follow up, up to 24 months.)
- Time to Progression(From the date of enrollment until end of follow up, up to 24 months.)
- Time to Progression of Patients According the Results of Biomarker BRCA1(From the date of enrollment until end of follow up, up to 24 months.)
- Time to Progression of Patients According the Results of Biomarker RAP80(From the date of enrollment until end of follow up, up to 24 months.)
- Time to Progression of Patients According the Results of Biomarker TS(From the date of enrollment until end of follow up, up to 24 months.)
- Overall Survival of Patients According the Results of Biomarker BRCA1(From the date of enrollment until end of follow up, up to 24 months.)
- Overall Survival of Patients According the Results of Biomarker RAP80(From the date of enrollment until end of follow up, up to 24 months.)
- Overall Survival of Patients According the Results of Biomarker TS(From the date of enrollment until end of follow up, up to 24 months.)
研究者
研究点 (8)
Loading locations...
相似试验
终止
2 期
Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial CancerMetastatic Urothelial CarcinomaNCT02693717M.D. Anderson Cancer Center7
已完成
2 期
Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaNCT01001910Albert Einstein College of Medicine22
已完成
2 期
A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung CancerNon Small Cell Lung CancerNCT01000480Eli Lilly and Company90
终止
2 期
Pemetrexed and Cisplatin as Treatment in Small Cell Lung CancerSmall Cell Lung CancerNCT00475657Eli Lilly and Company5
进行中（未招募）
不适用
Phase I study of cisplatin ? pemetrexed in combination with salazosulfapyridine targeting cancer stem cells in advanced non-squamous non-small cell lung cancerAdvanced non-squamous non-small cell lung cancer(Stage IIIB/IV or postoperative recurrent)JPRN-UMIN000017854Kyushu University Hospital30